Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365118 | 0.89 | ATM (0.73) | ATMCHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL743699 | 0.89 | ATM (0.73) | ATMCHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL743700 | 0.89 | ATM (0.73) | ATMCHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL28947431 | 0.82 | ATM (0.44) | ATMCHRM3CHRM2HRH3MEN1 | |
| SCHEMBL17465721 | 0.82 | ATM (0.44) | ATMCHRM3CHRM2HRH3MEN1 | |
| SCHEMBL28646559 | 0.82 | ATM (0.50) | ATMCHRM3CHRM2 | |
| SCHEMBL9906133 | 0.81 | ATM (0.43) | ATMCHRM3CHRM2HRH3CHRM1 | |
| SCHEMBL16014639 | 0.80 | ATM (1.00) | ATMCHRM3CHRM2 | |
| SCHEMBL19504740 | 0.79 | ATM (0.42) | ATMCHRM3HRH3MEN1KMT2A | |
| SCHEMBL2370044 | 0.79 | ATM (0.69) | ATMCHRM3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116783205-A | Compounds for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 尼坎治疗公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116478132-A | 2, 5-disubstituted and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors | 锐新医药公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20200339544-A1 | Epidermal growth factor receptor inhibitors | JOINT STOCK COMPANY "BIOCAD" (RU) | 2020-10-29 | — | — | US | disclosed |
| EP-3693365-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | Joint Stock Company "Biocad" (RU) | 2020-08-12 | — | — | EP | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| EP-2229377-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | Wyeth LLC (US) | 2010-09-22 | — | — | EP | disclosed |
| CN-101573327-A | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | KOREA RES INST CHEM TECH (KR) | 2009-11-04 | — | — | CN | disclosed |
| WO-2009076602-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | WYETH (US) | 2009-06-18 | — | — | WO | disclosed |
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-6903085-B1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | ASTRAZENECA, AB (CH) | 2005-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339544-A1 | Epidermal growth factor receptor inhibitors | EGFR, ERBB2, ERBB3 | ATM 2305/4885CHRM3 3507/4885CHRM2 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.